Prestwick’s Xenazine For Huntington’s Chorea Gets Positive Vote From FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Peripheral and CNS Drug advisory panel votes unanimously that adverse events associated with the Huntington’s disease treatment do not trump the drug’s proven efficacy.
You may also be interested in...
Prestwick Buyout Scores Huntington’s Drug For Biovail
Canadian company affirms prior deal that gave Ovation the U.S. rights to Xenazine.
Prestwick Buyout Scores Huntington’s Drug For Biovail
Canadian company affirms prior deal that gave Ovation the U.S. rights to Xenazine.
Merck Passes Huntington’s RNAi Program To Targeted Genetics
Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.